

FEBRUARY 2026

VOLUME 22, Issue 3

An expert review on 3D intracardiac echocardiography; biomimetic balloon-expandable THV in small aortic annuli; intra-annular TAVI in small aortic annuli; 5-year outcomes of transapical transcatheter mitral valve replacement; impact of coronary dominance on left main PCI prognosis; 5-year outcomes of the COMPARE trial; distal foot artery access compression; the retrieval of a stuck TAVI device; and more

Once again, EuroIntervention brings you an issue packed with study outcomes that not only push our thinking to evolve but help us to keep our patients at the centre of our decision-making.

3D ICE in structural heart disease

With the importance of three-dimensional intracardiac echocardiography (ICE) on the rise, **Sergio Berti, Ralph Stephan von Bardeleben and colleagues** review the most recent technical and procedural developments in a technology that is becoming integral to structural heart disease (SHD). This expert review covers the evolution of imaging in SHD, the current probes available for use, and training and workflow within different therapeutic subsets.

See page e136

Biomimetic balloon-expandable THV in small aortic annuli

Ole De Backer, Vinayak N. Bapat and colleagues report the 30-day procedural, clinical, and haemodynamic outcomes of the DurAVR transcatheter heart valve (THV) in patients with small aortic annuli. This novel balloon-expandable valve with a single-piece biomimetic leaflet design was associated with favourable haemodynamic outcomes and high technical and device success. This article is accompanied by an editorial from **Francesco Maisano**.

See page e150

Intra-annular TAVI in small aortic annuli

In a subanalysis of the NAVULTRA registry, **Stefano Cannata, Azeem Latib and colleagues** compare clinical outcomes and device performance of the self-expanding Navitor THV and the balloon-expandable SAPIEN 3 Ultra THV in patients with aortic stenosis and small aortic annuli undergoing transcatheter aortic valve implantation (TAVI). Despite comparable 1-year clinical outcomes, the Navitor demonstrated superior haemodynamic performance but higher rates of mild paravalvular leak and new permanent pacemaker implantation.

See page e161

Intrepid transapical TMVR 5-year outcomes

In examining the 5-year outcomes of the Intrepid transapical transcatheter mitral valve replacement (TMVR) system used in selected patients with symptomatic \geq moderate-severe mitral regurgitation (MR), **Gilbert H.L. Tang, Michael J. Reardon and colleagues** confirmed sustained MR elimination, durable haemodynamic valve performance, and improved functional status. **Marianna Adamo and Elisa Pezzola** contribute an editorial on this article.

See page e172

Also in this issue

Yingyang Geng, Lei Song and colleagues on the impact of coronary dominance on left main percutaneous coronary intervention (PCI) prognosis; **Tim Wittig, Sabine Steiner and colleagues** on the 5-year results of the COMPARE trial; **Róbert Bellavics, Zoltán Ruzsa and colleagues** on distal foot artery access compression in lower limb angioplasty; and more

See page e183